XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues      
Sales of goods   $ 0 $ 0
Total revenue   0 0
Cost of goods sold and operating Expenses      
Cost of goods sold   0 0
Research and development $ 3,994 3,773 6,658
General and administrative 4,356 2,879 5,846
Total operating expenses 8,350 6,652 12,504
Loss from operations (8,350) (6,652) (12,504)
Other income (expense)      
Loss on conversion of debt (440)    
Other income 0 113 0
Finance income 7 6 6
Finance costs (58) (28) (20)
Operating lease interest expense (3) (15) (19)
Loss before income taxes (8,844) (6,576) (12,537)
Income tax provision (recovery) 0 0 0
Net loss (8,844) (6,576) (12,537)
Attributable to: Net loss attributable to Nymox shareholders $ (8,844) $ (6,576) $ (12,537)
Basic and diluted loss per share $ (0.10) $ (0.07) $ (0.15)
Weighted average number of common shares outstanding 91,687,400 89,383 81,976